Advertisement

Topics

These highlights do not include all the information needed to use CLINIMIX safely and effectively. See full prescribing information for CLINIMIX. CLINIMIX (amino acids in dextrose) injection, for intravenous use Initial U.S. Approval: 1997 | CLINIMIX [Baxter Healthcare Corporation] | BioPortfolio

12:50 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

CLINIMIX is indicated as a source of calories and protein for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX may be used to treat negative nitrogen balance in patients.

For single dose only. Discard unused portion.

Figures 1–4:

Instructions on Storage

Storage After Removal of Overwrap:

Once removed from the protective clear overwrap, mixed (peel seal activated) or unmixed (peel seal intact) CLINIMIX solutions may be stored under refrigeration for up to 9 days.

Storage Once any Additive is Added:

Use promptly after mixing. Any storage with additives should be under refrigeration and limited to a brief period of time, less than 24 hours. After removal from refrigeration, use promptly and complete the infusion within 24 hours. Any remaining mixture must be discarded.

Storage Once Lipids are Added:

Use promptly after mixing. Any storage with additives should be under refrigeration and limited to a brief period of time, no longer than 24 hours. After removal from refrigeration, use promptly and complete the infusion within 24 hours. Any mixture remaining must be discarded.

The recommended daily nutritional requirements for protein and dextrose compared to the amount of nutrition provided by CLINIMIX are shown in Table 1 .

As indicated on an individual basis, maintenance vitamins, electrolytes, trace elements and other components (including lipids) should be administered as required to prevent deficiencies and complications from developing.

The maximum infusion rates in adult patients are show in Table 2.

In addition to meeting protein needs, the administration rate should be governed, especially during the first few day of therapy, by the patient’s tolerance to dextrose. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of blood glucose levels.

Table 1: Nutritional Comparison –Adult Patients
Recommended Nutritional Requirements Recommended CLINIMIX Adult Dosage
Stable Patients Critically Ill Patients Do not use in patients with conditions that are contraindicated [see Contraindications (4) ]. CLINIMIX 4.25/5 CLINIMIX 4.25/10 CLINIMIX 5/15 CLINIMIX 5/20
Fluid (mL/kg/day) 30 to 40 Minimum needed to deliver adequate nutrition 19 to 40 19 to 40 16 to 40 16 to 40
Protein Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein.(g/kg/day) (Nitrogen g/kg/day) 0.8 to 1 (0.13 to 0.16) 1.5 to 2 (0.24 to 0.32) 0.8 to 1.7 (0.13 to 0.27) 0.8 to 1.7 (0.13 to 0.27) 0.8 to 2 (0.13 to 0.32) 0.8 to 2 (0.13 to 0.32)
Dextrose (g/kg/day) ≤10 ≤5.8 0.95 to 2 1.9 to 4 2.4 to 6 3.2 to 8
Table 2: Maximum Infusion Rate in Adult Patients:
Maximum Infusion Rates in Adults Patients
CLINIMIX 4.25/5 CLINIMIX 4.25/10 CLINIMIX 5/15 CLINIMIX 5/20
Maximum Infusion Rate (mL/kg/hour) 2.4 2.4 1.67 1.25
Corresponding infusion rate Amino Acid (g/kg/hour) 0.1Rate limiting factor 0.1 0.08 0.06
Dextrose (g/kg/hour) 0.12 0.24 0.25 0.25

Prior to administration, correct severe fluid or electrolyte imbalances. Closely monitor serum electrolyte levels and adjust the volume of CLINIMIX administered as required [see Warnings and Precautions (5.10)].

Patients with renal impairment not needing dialysis require 0.6 to 0.8 g of protein/kg/day. Serum electrolyte levels should be closely monitored. Patients on hemodialysis or continuous renal replacement therapy should receive 1.2 to 1.8 g of protein/kg/day up to a maximum of 2.5 g of protein/kg/day based on nutritional status and estimated protein losses. The CLINIMIX dosage can be adjusted based on the severity of renal impairment, supplementing protein as indicated. If required, additional amino acids may be added to the CLINIMIX container or infused separately. Compatibility of additions should be evaluated by a pharmacist and questions may be directed to Baxter.

The dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia [see Use in Specific Populations (8.4)]. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. The infusion rate and volume should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.

In pediatric patients, CLINIMIX is dosed on the basis of protein provided as amino acids. The recommended dosage, by age group is provided in Tables 3 - 6. Infusion rates are based on protein and do not take carbohydrates, fluid or electrolytes into consideration.

This product does not contain the amino acids cysteine and taurine, considered conditionally essential for neonates and infants. If possible, these amino acids should be added to this product if used in this pediatric population.

Table 3: Preterm and Term Infants Less than 1 Month of Age
Recommended Nutritional Requirements1 Recommended CLINIMIX Dosage in Preterm and Term Infants Less than 1 Month of Age
CLINIMIX 4.25/5 CLINIMIX4.25/10 CLINIMIX 5/15 CLINIMIX 5/20
Infusion Rate Range (mL/kg/hr) 2.9 to 3.9 2.9 to 3.9 2.5 to 3.3 2.5 to 3.3
Fluid (mL/kg/day) 100 to 150 70 to 94 70 to 94 60 to 79 60 to 79
Protein Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein. (g/kg/day) (Nitrogen g/kg/day) 3 to 4 (0.48 to 0.64) 3 to 4 (0.48 to 0.64) 3 to 4 (0.48 to 0.64) 3 to 4 (0.48 to 0.64) 3 to 4 (0.48 to 0.64)
Dextrose (g/kg/day) 7 to 20 3.5 to 4.7 7 to 9.4 9 to 11.9 12 to 15.8
Table 4: Pediatric Patients 1 Month to Less than 1 Year of Age
Recommended Nutritional Requirements1 Recommended CLINIMIX Dosage in Pediatric Patients 1 Month to Less than 1 Year of Age
CLINIMIX 4.25/5 CLINIMIX 4.25/10 CLINIMIX 5/15 CLINIMIX 5/20
Infusion Rate Range (mL/kg/hr) 2 to 2.9 2 to 2.9 1.7 to 2.5 1.7 to 2.5
Fluid (mL/kg/day) 100 mL/kg for the first 10 kg + 50 mL/kg for the second 10 kg. 48 to 70 48 to 70 41 to 60 41 to 60
Protein Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein (g/kg/day) (Nitrogen g/kg/day) 2 to 3 (0.32 to 0.48) 2 to 3 (0.32 to 0.48) 2 to 3 (0.32 to 0.48) 2 to 3 (0.32 to 0.48) 2 to 3 (0.32 to 0.48)
Dextrose (g/kg/day) 7 to 20 2.4 to 3.5 4.8 to 7 6.1 to 9 8.2 to 12
Table 5: Pediatric Patients 1 Year to Less than 11 Years of Age
Recommended Nutritional Requirements1 Recommend CLINIMIX Dosage in Pediatric Patients 1 Year to Less than 11 Years of Age
CLINIMIX 4.25/5 CLINIMIX 4.25/10 CLINIMIX 5/15 CLINIMIX 5/20
Infusion Rate Range (mL/kg/hr) 1 to 2 1 to 2 0.8 to 1.7 0.8 to 1.7
Fluid (mL/kg/day) 100 mL/kg for the first 10 kg + 50 mL/kg for the second 10 kg + 20 mL/kg for weight > 20 kg 24 to 48 24 to 48 19 to 41 19 to 41
Protein Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein.(g/kg/day) (Nitrogen g/kg/day) 1 to 2 (0.16 to 0.32) 1 to 2 (0.16 to 0.32) 1 to 2 (0.16 to 0.32) 1 to 2 (0.16 to 0.32) 1 to 2 (0.16 to 0.32)
Dextrose (g/kg/day) 7 to 14 1.2 to 2.4 2.4 to 4.8 2.9 to 6.1 3.8 to 8.2
Table 6: Pediatric Patients 11 Years to 17 Years of Age
Recommended Nutritional Requirements1 Recommended CLINIMIX Dosage in Pediatric Patients 11 Years to 17 Years of Age
CLINIMIX 4.25/5 CLINIMIX 4.25/10 CLINIMIX 5/15 CLINIMIX 5/20
Infusion Rate Range (mL/kg/hr) 0.8 to 1.5 0.8 to 1.5 0.7 to 1.3 0.7 to 1.3
Fluid (mL/kg/day) 100 mL/kg for the first 10 kg + 50 mL/kg for the second 10 kg + 20 mL/kg for weight > 20 kg 19 to 36 19 to 36 17 to 31 17 to 31
Protein Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein.(g/kg/day) (Nitrogen g/kg/day) 0.8 to 1.5 (0.13 to 0.24) 0.8 to 1.5 (0.13 to 0.24) 0.8 to 1.5 (0.13 to 0.24) 0.8 to 1.5 (0.13 to 0.24) 0.8 to 1.5 (0.13 to 0.24)
Dextrose (g/kg/day) 5 to 9 1 to 1.8 1.9 to 3.6 2.5 to 4.7 3.4 to 6.2

To reduce the risk of hypoglycemia after discontinuation, a gradual decrease in flow rate in the last hour of infusion should be considered.

CLINIMIX is available in 1000 mL and 2000 mL dual chamber containers. The individual chambers contain essential and nonessential amino acids and dextrose. Table 7 describes the individual components of CLINIMIX.

Essential Amino Acids (mg/100 mL) Nonessential Amino Acids
(mg/100 mL) Anion Profile (mEq/L) Balanced by ions from amino acids. (kcal/L)
Table 7 INGREDIENTS PER 100mL OF CLINIMIX
Strength of CLINIMIX CLINIMIX 4.25/5 sulfite‑free
(4.25% Amino Acid in 5% Dextrose) Injection
CLINIMIX 4.25/10 sulfite‑free
(4.25% Amino Acid in 10% Dextrose) Injection
CLINIMIX 5/15 sulfite‑free
(5% Amino Acid in 15% Dextrose) Injection
CLINIMIX 5/20 sulfite‑free
(5% Amino Acid in 20% Dextrose) Injection
Dextrose Hydrous, USP (g/100 mL) 5 10 15 20
Amino Acids (g/100 mL) 4.25 4.25 5 5
Total Nitrogen (mg/100 mL) 702 702 826 826
 
Leucine 311 311 365 365
Isoleucine 255 255 300 300
Valine 247 247 290 290
Lysine (added as the hydrochloride salt) 247 247 290 290
Phenylalanine 238 238 280 280
Histidine 204 204 240 240
Threonine 179 179 210 210
Methionine 170 170 200 200
Tryptophan 77 77 90 90
 
Alanine 880 880 1035 1035
Arginine 489 489 575 575
Glycine 438 438 515 515
Proline 289 289 340 340
Serine 213 213 250 250
Tyrosine 17 17 20 20
   
AcetateDerived from glacial acetic acid (for pH adjustment) and sodium acetate. 37 37 42 42
ChlorideContributed by calcium chloride, lysine hydrochloride, magnesium chloride, and sodium chloride. 17 17 20 20
pHpH of sulfite-free amino acid injection in the outlet port chamber was adjusted with glacial acetic acid.(Range) 6.0 (4.5 to 7.0) 6.0 (4.5 to 7.0) 6.0 (4.5 to 7.0) 6.0 (4.5 to 7.0)
Osmolarity (mOsmol/L) (calc) 675 930 1255 1505
Caloric Content
 
From Dextrose 170 340 510 680
From Amino Acids 170 170 200 200
TOTAL (Dextrose and Amino Acids) 340 510 710 880

The use of CLINIMIX is contraindicated in:

Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. In some cases, fatal outcomes due to pulmonary embolism have occurred. CLINIMIX contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates. Precipitates have been reported even in the absence of phosphate salt in the solution. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. In addition to inspection of the solution [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)], the infusion set and catheter should also periodically be checked for precipitates.

Hypersensitivity/infusion reactions including anaphylaxis have been reported with CLINIMIX. Stop infusion immediately and treat patient accordingly if any signs or symptoms of a hypersensitivity reaction develop. Signs or symptoms may include: hypotension, hypertension, peripheral cyanosis, tachycardia, dyspnea, vomiting, nausea, urticaria, rash, pruritus, erythema, hyperhidrosis, pyrexia, and chills.

Monitor for signs and symptoms (including fever and chills) of early infections, including laboratory test results (including leukocytosis and hyperglycemia) and frequent checks of the parenteral access device and insertion site for edema, redness and discharge.

Refeeding severely undernourished patients may result in refeeding syndrome, characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intakes.

When using CLINIMIX in patients with diabetes mellitus, impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death. Patients with underlying confusion and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state. Monitor blood glucose levels and treat hyperglycemia to maintain optimum levels while administering CLINIMIX. Insulin may be administered or adjusted to maintain optimal blood glucose levels during CLINIMIX administration.

Solutions with osmolarity of 900 mOsm/L or greater must be infused through a central catheter. CLINIMIX solutions containing more than 5% dextrose have an osmolarity greater than or equal to 900 mOsm/L. CLINIMIX 4.25/10, 5/15 and 5/20 are indicated for administration into a central vein only, such as the superior vena cava [see Dosage and Administration (2.2)]. The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis.

CLINIMIX 4.25/5 is indicated for peripheral administration, or may be infused into a central vein [see Dosage and Administration (2.2)]. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.

Hepatobiliary disorders are known to develop in some patients without preexisting liver disease who receive parenteral nutrition, including cholecystitis, cholelithiasis, cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure. The etiology of these disorders is thought to be multifactorial and may differ between patients.

Increase in blood ammonia levels and hyperammonemia may occur in patients receiving amino acid solutions. In some patients this may indicate hepatic insufficiency or the presence of an inborn error of amino acid metabolism [see Contraindications (4) .]

Monitor liver function parameters and ammonia levels. Patients developing signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.

CLINIMIX contains no more than 25 mcg/L of aluminum. However, with prolonged parenteral administration in patients with renal impairment, the aluminum contained in CLINIMIX may reach toxic levels. Preterm infants are at a greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Patients with renal impairment, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis. The exact etiology is unknown and is likely multifactorial. If CLINIMIX treated patients develop liver test abnormalities consider discontinuation or dosage reduction.

Patients with renal impairment, such as pre-renal azotemia, renal obstruction, and protein-losing nephropathy may be at increased risk of electrolyte and fluid volume imbalance. Patients with cardiac insufficiency due to left ventricular systolic dysfunction are susceptible to excess fluid accumulation. Use CLINIMIX with caution in patients with cardiac insufficiency or renal impairment. CLINIMIX dosage may require adjustment with specific attention to fluid, protein, and electrolyte content in these patients.

Monitor renal function parameters. Patients developing signs of renal impairment should be assessed early by a clinician knowledgeable in renal disease in order to determine the appropriate CLINIMIX dosage and other treatment options.

Monitor fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters throughout treatment.

Patients receiving CLINIMIX should be monitored frequently and their electrolyte requirements individualized.

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.

The following adverse reactions from voluntary reports or clinical studies have been reported with CLINIMIX. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Risk Summary

There are no adequate or well-controlled studies in pregnant women with CLINIMIX. Additionally, animal reproduction studies have not been conducted with amino acids and electrolytes and dextrose. It is not known whether CLINIMIX can cause fetal harm when administered to a pregnant woman.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. However, the estimated background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.

Clinical Considerations

Disease-Associated Maternal and/or Embryo-Fetal Risk

Based on clinical practice guidelines, parenteral nutrition should be considered in cases of severe maternal malnutrition where nutritional requirements cannot be fulfilled by the enteral route because of the risks to the fetus associated with severe malnutrition, such as preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality.

Risk Summary

It is not known whether CLINIMIX is present in human milk. There are no data on the effects of CLINIMIX on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CLINIMIX and any potential adverse effects on the breastfed child from CLINIMIX or from the underlying maternal condition.

Safety and effectiveness of CLINIMIX in pediatric patients have not been established by adequate and well-controlled studies. Use of dextrose, amino acid infusions and electrolytes in pediatric patients is based on clinical practice [see Dosage and Administration (2.8)].

Newborns, especially those born premature and with low birth weight, are at increased risk of developing hypo – or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death. Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes.

Because of immature renal function, preterm infants receiving prolonged treatment with CLINIMIX may be at risk of aluminum toxicity [see Warnings and Precautions (5.8)].

Patients, including pediatric patients, may be at risk for Parenteral Nutrition Associated Liver Disease (PNALD) [see Warnings and Precautions (5.9)].

Hyperammonemia is of special significance in infants (birth to two years). This reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. It is essential that blood ammonia be measured frequently in infants [See Warnings and Precautions (5.7) ].

Clinical studies of CLINIMIX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from other younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

An increased infusion rate of CLINIMIX cause hyperglycemia, hyperosmolality, and adverse effects on water and electrolyte balance [see Warnings and Precautions (5.5, 5.10)].

Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal.

Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to respiratory and cardiovascular systems.

For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.

CLINIMIX sulfite-free (amino acids in dextrose) injection for intravenous use consists of sterile, nonpyrogenic, hypertonic solutions in a dual chamber container.

The outlet port chamber contains essential and nonessential amino acids. The formulas for the individual amino acids found in CLINIMIX sulfite-free (amino acids in dextrose) injections are provided in Table 8.

The injection port chamber contains dextrose. Dextrose, USP, is chemically designated D-glucose, monohydrate (CHO • HO) and has the following structure:

Table 8: Formulas for Amino Acids
Essential Amino Acids
Leucine (CH3)2 CHCH2CH (NH2) COOH
Isoleucine CH3CH2CH (CH3) CH (NH2) COOH
Valine (CH3)2 CHCH (NH2) COOH
Lysine (added as the hydrochloride salt) H2N (CH2)4 CH (NH2) COOH
Phenylalanine (C6H5) CH2 CH (NH2) COOH
Histadine (C3H3N2) CH2CH (NH2) COOH
Threonine CH3CH (OH) CH (NH2) COO
Methionine CH3S (CH2)2 CH (NH2) COOH
Tryptophan (C8H6N) CH2 CH (NH2) COOH
Nonessential Amino Acids
Alanine CH3CH (NH2) COOH
Arginine H2NC (NH) NH (CH2)3 CH (NH2) COOH
Glycine H2NCH2COOH
Proline [(CH2)3 NH CH] COOH
Serine HOCH2CH (NH2) COOH
Tyrosine [C6H4 (OH)] CH2CH (NH2) COOH

CLINIMIX is used as a supplement of nutrition in patients, providing macronutrients (amino acids and dextrose) parenterally.

The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy.

The administered dextrose is oxidized to carbon dioxide and water, yielding energy.

The disposition of infused amino acids and dextrose, are essentially the same as those absorbed from ordinary food.

CLINIMIX (amino acids in dextrose) injection (sulfite-free) is available in 1000 mL and 2000mL volumes (See Table 9).

Minimize exposure of CLINIMIX to heat and avoid excessive heat.

Protect from freezing.

Store CLINIMIX at room temperature (25°C/77°F) (may briefly store at up to 40°C/104°F).

Refrigerated storage is limited to 9 days once the protective clear overwrap has been opened.

Do not use if the protective clear overwrap has been previously opened or damaged.

For storage of admixed solutions see Dosage and Administration (2.3, 2.4).

After mixing, the product represents 1000 mL Code and NDC Number 2000 mL Code and NDC Number CLINIMIX 4.25/5 sulfite‑free
(4.25% Amino Acid in 5% Dextrose) InjectionCode 2B7726
NDC 0338‑1133‑03Code 2B7704
NDC 0338‑1089‑04CLINIMIX 4.25/10 sulfite‑free
(4.25% Amino Acid in 10% Dextrose) InjectionCode 2B7727
NDC 0338‑1134‑03Code 2B7705
NDC 0338‑1091‑04CLINIMIX 5/15 sulfite‑free
(5% Amino Acid in 15% Dextrose) InjectionCode 2B7730
NDC 0338‑1137‑03Code 2B7709
NDC 0338‑1099‑04CLINIMIX 5/20 sulfite‑free
(5% Amino Acid in 20% Dextrose) InjectionCode 2B7731
NDC 0338‑1138‑03Code 2B7710
NDC 0338‑1101‑04
Table 9: CLINIMIX Formulations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Inform patients, caregivers, or home healthcare providers of the following risks of CLINIMIX:

LOT EXP

2B7728 NDC 0338-1132-03

CLINIMIX 2.75/5 SULFITE-FREE

(2.75% Amino Acid in 5% Dextrose) Injection

500 mL INJECTION PORT CHAMBER10% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER5.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONSON ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITYAND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXEDINJECTION

DEXTROSE HYDROUS USP 5 g

ESSENTIAL AMINO ACIDS LEUCINE 201 mgISOLEUCINE 165 mgVALINE 160 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 159 mgPHENYLALANINE 154 mgHISTIDINE 132 mgTHREONINE 116 mgMETHIONINE 110 mgTRYPTOPHAN 50 mg

NONESSENTIAL AMINO ACIDS ALANINE 570 mgARGININE 316 mgGLYCINE 283 mgPROLINE 187 mgSERINE 138 mgTYROSINE 11 mg

mEq/LACETATE 24CHLORIDE 11

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USAMADE IN USA

LOT EXP2B7727 NDC 0338-1134-03

CLINIMIX 4.25/10 SULFITE-FREE

(4.25% Amino Acids in 10% Dextrose) Injection

500 mL INJECTION PORT CHAMBER20% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ONACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITYAND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXEDINJECTION

DEXTROSE HYDROUS USP 10 g

ESSENTIAL AMINO ACIDS

LEUCINE 311 mg

ISOLEUCINE 255 mg

VALINE 247 mg

LYSINE (ADDED AS THE

HYDROCHLORIDE SALT) 247 mg

PHENYLALANINE 238 mg

HISTIDINE 204 mg

THREONINE 179 mg

METHIONINE 170 mg

TRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS

ALANINE 880 mg

ARGININE 489 mg

GLYCINE 438 mg

PROLINE 289 mg

SERINE 213 mg

TYROSINE 17 mg

mEq/L

ACETATE 37

CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS

pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE

SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)AVOID EXCESSIVE HEATPROTECT FROM FREEZINGSEE PRESCRIBING INFORMATION

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USAMADE IN USA

LOT EXP

2B7701 NDC 0338-1083-04

CLINIMIX 2.75/5 sulfite-free (2.75% Amino Acid in 5% Dextrose) Injection

1000 mL INJECTION PORT CHAMBER10% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER5.5% Amino Acid Injection

Rx Only

CHECK FOR MINUTE LEAKS BY SQUEEZING

EACH CHAMBER OF THE BAG

BEFORE USE GRASP EACH SIDE OF

THE TOP OF THE BAG AND ROLL BAG

TO OPEN SEAL BETWEEN CHAMBERS

MIX THOROUGHLY

AFTER MIXING THE PRODUCT

REPRESENTS 2000 mL

ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH

PHARMACIST IF AVAILABLE WHEN INTRODUCING

ADDITIVES USE ASEPTIC TECHNIQUE

MIX THOROUGHLY DO NOT STORE

DOSAGE INTRAVENOUSLY AS DIRECTED BY A

PHYSICIAN DO NOT USE UNLESS SOLUTION IS

CLEAR REFRIGERATED STORAGE AFTER MIXING

LIMITED TO 24 HOURS DISCARD UNUSED PORTION

SEE ACCOMPANYING DIRECTIONS FOR USE

CAUTIONS MUST NOT BE USED IN SERIES

CONNECTIONS DISCONTINUE INFUSION

IF ADVERSE REACTION OCCURS

CLARITY DUAL CHAMBER CONTAINER PL 2401 PLASTIC

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 5 g

ESSENTIAL AMINO ACIDS LEUCINE 201 mgISOLEUCINE 165 mgVALINE 160 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 159 mgPHENYLALANINE 154 mgHISTIDINE 132 mgTHREONINE 116 mgMETHIONINE 110 mgTRYPTOPHAN 50 mg

NONESSENTIAL AMINO ACIDS ALANINE 570 mgARGININE 316 mgGLYCINE 283 mgPROLINE 187 mgSERINE 138 mgTYROSINE 11 mg

mEq/LACETATE 24CHLORIDE 11

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

pH 6.0 (4.5 TO 7.0) HYPERTONIC

OSMOLARITY 525 mOsmol/L (CALC)

STERILE NONPYROGENIC

SINGLE DOSE CONTAINER

Baxter BAXTER HEALTHCARE CORPORATION CLINTEC NUTRITION DIVISION DEERFIELD IL 60015 USA MADE IN USA PATENT PENDING BAXTER CLINIMIX AND CLARITY ARE TRADEMARKS OF BAXTER INTERNATIONAL INC

LOT EXP

2B7726 NDC 0338-1133-03

CLINIMIX

4.25/5

SULFITE-FREE

(4.25% Amino Acidsin 5% Dextrose)Injection

500 mL INJECTION PORT CHAMBER10% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER8.5% Amino Acid Injection

ACTIVATE SEAL ANDMIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED

INJECTION

DEXTROSE HYDROUS USP 5 g

ESSENTIAL AMINO ACIDS

LEUCINE 311 mg

ISOLEUCINE 255 mg

VALINE 247 mg

LYSINE (ADDED AS THE

HYDROCHLORIDE SALT) 247 mg

PHENYLALANINE 238 mg

HISTIDINE 204 mg

THREONINE 179 mg

METHIONINE 170 mg

TRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS

ALANINE 880 mg

ARGININE 489 mg

GLYCINE 438 mg

PROLINE 289 mg

SERINE 213 mg

TYROSINE 17 mg

mEq/L

ACETATE 37

CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS

pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)AVOID EXCESSIVE HEATPROTECT FROM FREEZINGSEE PRESCRIBING INFORMATION

Baxter

BAXTER HEALTHCARE CORPORATIONDEERFIELD IL 60015 USAMADE IN USA

LOT EXP

2B7704 NDC 0338-1089-04

CLINIMIX 4.25/5 SULFITE-FREE (4.25% Amino Acid in 5% Dextrose) Injection

1000 mL INJECTION PORT CHAMBER10% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 5 g

ESSENTIAL AMINO ACIDS LEUCINE 311 mgISOLEUCINE 255 mgVALINE 247 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 247 mgPHENYLALANINE 238 mgHISTIDINE 204 mgTHREONINE 179 mgMETHIONINE 170 mgTRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS ALANINE 880 mgARGININE 489 mgGLYCINE 438 mgPROLINE 289 mgSERINE 213 mgTYROSINE 17 mg

mEq/LACETATE 37CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)AVOID EXCESSIVE HEATPROTECT FROM FREEZINGSEE PRESCRIBING INFORMATION

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

Container Label

LOT EXP

2B7705 NDC 0338-1091-04

CLINIMIX 4.25/10 SULFITE-FREE (4.25% Amino Acid in 10% Dextrose) Injection

1000 mL INJECTION PORT CHAMBER20% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 10 g

ESSENTIAL AMINO ACIDS LEUCINE 311 mgISOLEUCINE 255 mgVALINE 247 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 247 mgPHENYLALANINE 238 mgHISTIDINE 204 mgTHREONINE 179 mgMETHIONINE 170 mgTRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS ALANINE 880 mgARGININE 489 mgGLYCINE 438 mgPROLINE 289 mgSERINE 213 mgTYROSINE 17 mg

mEq/LACETATE 37CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)AVOID EXCESSIVE HEATPROTECT FROM FREEZINGSEE PRESCRIBING INFORMATION

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7728 NDC 0338-1035-03

CLINIMIX 4.25/20 SULFITE-FREE (4.25% Amino Acid in 20% Dextrose) Injection

500 mL INJECTION PORT CHAMBER40% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 20 g

ESSENTIAL AMINO ACIDS LEUCINE 311 mgISOLEUCINE 255 mgVALINE 247 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 247 mgPHENYLALANINE 238 mgHISTIDINE 204 mgTHREONINE 179 mgMETHIONINE 170 mgTRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS ALANINE 880 mgARGININE 489 mgGLYCINE 438 mgPROLINE 289 mgSERINE 213 mgTYROSINE 17 mg

mEq/LACETATE 37CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7706 NDC 0338-1093-04

CLINIMIX 4.25/20 SULFITE-FREE (4.25% Amino Acid in 20% Dextrose) Injection

1000 mL INJECTION PORT CHAMBER40% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 20 g

ESSENTIAL AMINO ACIDS LEUCINE 311 mgISOLEUCINE 255 mgVALINE 247 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 247 mgPHENYLALANINE 238 mgHISTIDINE 204 mgTHREONINE 179 mgMETHIONINE 170 mgTRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS ALANINE 880 mgARGININE 489 mgGLYCINE 438 mgPROLINE 289 mgSERINE 213 mgTYROSINE 17 mg

mEq/LACETATE 37CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7729 NDC 0338-1136-03

CLINIMIX 4.25/25 SULFITE-FREE (4.25% Amino Acid in 25% Dextrose) Injection

500 mL INJECTION PORT CHAMBER50% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 25 g

ESSENTIAL AMINO ACIDS LEUCINE 311 mgISOLEUCINE 255 mgVALINE 247 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 247 mgPHENYLALANINE 238 mgHISTIDINE 204 mgTHREONINE 179 mgMETHIONINE 170 mgTRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS ALANINE 880 mgARGININE 489 mgGLYCINE 438 mgPROLINE 289 mgSERINE 213 mgTYROSINE 17 mg

mEq/LACETATE 37CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7707 NDC 0338-1095-04

CLINIMIX 4.25/25 SULFITE-FREE (4.25% Amino Acid in 25% Dextrose) Injection

1000 mL INJECTION PORT CHAMBER50% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 25 g

ESSENTIAL AMINO ACIDS LEUCINE 311 mgISOLEUCINE 255 mgVALINE 247 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 247 mgPHENYLALANINE 238 mgHISTIDINE 204 mgTHREONINE 179 mgMETHIONINE 170 mgTRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS ALANINE 880 mgARGININE 489 mgGLYCINE 438 mgPROLINE 289 mgSERINE 213 mgTYROSINE 17 mg

mEq/LACETATE 37CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7730 NDC 0338-1137-03

CLINIMIX 5/15 SULFITE-FREE (5% Amino Acid in 15% Dextrose) Injection

500 mL INJECTION PORT CHAMBER30% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 15 g

ESSENTIAL AMINO ACIDS LEUCINE 365 mgISOLEUCINE 300 mgVALINE 290 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 290 mgPHENYLALANINE 280 mgHISTIDINE 240 mgTHREONINE 210 mgMETHIONINE 200 mgTRYPTOPHAN 90 mg

NONESSENTIAL AMINO ACIDS ALANINE 1035 mgARGININE 575 mgGLYCINE 515 mgPROLINE 340 mgSERINE 250 mgTYROSINE 20 mg

mEq/LACETATE 42CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)AVOID EXCESSIVE HEATPROTECT FROM FREEZINGSEE PRESCRIBING INFORMATION

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7709 NDC 0338-1099-04

CLINIMIX 5/15 SULFITE-FREE (5% Amino Acid in 15% Dextrose) Injection

1000 mL INJECTION PORT CHAMBER30% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 15 g

ESSENTIAL AMINO ACIDS LEUCINE 365 mgISOLEUCINE 300 mgVALINE 290 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 290 mgPHENYLALANINE 280 mgHISTIDINE 240 mgTHREONINE 210 mgMETHIONINE 200 mgTRYPTOPHAN 90 mg

NONESSENTIAL AMINO ACIDS ALANINE 1035 mgARGININE 575 mgGLYCINE 515 mgPROLINE 340 mgSERINE 250 mgTYROSINE 20 mg

mEq/LACETATE 42CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)AVOID EXCESSIVE HEATPROTECT FROM FREEZINGSEE PRESCRIBING INFORMATION

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7731 NDC 0338-1138-03

CLINIMIX 5/ SULFITE-FREE (5% Amino Acid in 20% Dextrose) Injection

500 mL INJECTION PORT CHAMBER40% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 20 g

ESSENTIAL AMINO ACIDS LEUCINE 365 mgISOLEUCINE 300 mgVALINE 290 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 290 mgPHENYLALANINE 280 mgHISTIDINE 240 mgTHREONINE 210 mgMETHIONINE 200 mgTRYPTOPHAN 90 mg

NONESSENTIAL AMINO ACIDS ALANINE 1035 mgARGININE 575 mgGLYCINE 515 mgPROLINE 340 mgSERINE 250 mgTYROSINE 20 mg

mEq/LACETATE 42CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)AVOID EXCESSIVE HEATPROTECT FROM FREEZINGSEE PRESCRIBING INFORMATION

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7710 NDC 0338-1101-04

CLINIMIX 5/20 SULFITE-FREE (5% Amino Acid in 20% Dextrose) Injection

1000 mL INJECTION PORT CHAMBER40% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 20 g

ESSENTIAL AMINO ACIDS LEUCINE 365 mgISOLEUCINE 300 mgVALINE 290 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 290 mgPHENYLALANINE 280 mgHISTIDINE 240 mgTHREONINE 210 mgMETHIONINE 200 mgTRYPTOPHAN 90 mg

NONESSENTIAL AMINO ACIDS ALANINE 1035 mgARGININE 575 mgGLYCINE 515 mgPROLINE 340 mgSERINE 250 mgTYROSINE 20 mg

mEq/LACETATE 42CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)AVOID EXCESSIVE HEATPROTECT FROM FREEZINGSEE PRESCRIBING INFORMATION

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7732 NDC 0338-1139-03

CLINIMIX 5/25 SULFITE-FREE (5% Amino Acid in 25% Dextrose) Injection

500 mL INJECTION PORT CHAMBER50% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 25 g

ESSENTIAL AMINO ACIDS LEUCINE 365 mgISOLEUCINE 300 mgVALINE 290 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 290 mgPHENYLALANINE 280 mgHISTIDINE 240 mgTHREONINE 210 mgMETHIONINE 200 mgTRYPTOPHAN 90 mg

NONESSENTIAL AMINO ACIDS ALANINE 1035 mgARGININE 575 mgGLYCINE 515 mgPROLINE 340 mgSERINE 250 mgTYROSINE 20 mg

mEq/LACETATE 42CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

LOT EXP

2B7711 NDC 0338-1103-04

CLINIMIX 5/25 SULFITE-FREE (5% Amino Acid in 25% Dextrose) Injection

1000 mL INJECTION PORT CHAMBER50% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION

DEXTROSE HYDROUS USP 25 g

ESSENTIAL AMINO ACIDS LEUCINE 365 mgISOLEUCINE 300 mgVALINE 290 mgLYSINE (ADDED AS THEHYDROCHLORIDE SALT) 290 mgPHENYLALANINE 280 mgHISTIDINE 240 mgTHREONINE 210 mgMETHIONINE 200 mgTRYPTOPHAN 90 mg

NONESSENTIAL AMINO ACIDS ALANINE 1035 mgARGININE 575 mgGLYCINE 515 mgPROLINE 340 mgSERINE 250 mgTYROSINE 20 mg

mEq/LACETATE 42CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDSpH ADJUSTED WITH GLACIAL ACETIC ACID

STERILESINGLE DOSE CONTAINER

Baxter BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA

Manufacturer

Baxter Healthcare Corporation

Active Ingredients

Source

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Clinimix [baxter healthcare corporation]

Clinimix, solution for infusion

Clinimix e [baxter healthcare corporation]

These highlights do not include all the information needed to use CLINIMIX E safely and effectively. See full prescribing information for CLINIMIX E. CLINIMIX E (amino acids with electrolytes in dextr...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients

In critically ill patients, a strategy aimed at an early delivery of full caloric support, with a combination of Enteral Nutrition (EN) and Parenteral Nutrition (PN) (in conditions prevent...

PubMed Articles [0 Results]

None

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record